S
Sung-Bae Kim
Researcher at University of Ulsan
Publications - 346
Citations - 13296
Sung-Bae Kim is an academic researcher from University of Ulsan. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 38, co-authored 285 publications receiving 10005 citations. Previous affiliations of Sung-Bae Kim include Seoul National University & Yonsei University.
Papers
More filters
Journal ArticleDOI
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
José Baselga,Javier Cortes,Sung-Bae Kim,Seock-Ah Im,Roberto Hegg,Young-Hyuck Im,L Roman,Jose Luiz Pedrini,Tadeusz Pienkowski,Adam Knott,Emma Clark,Mark C. Benyunes,Graham Ross,Sandra M. Swain +13 more
TL;DR: The combination of pertuzumab plus trastuzumAB plus docetaxel, when used as first-line treatment for HER2-positive metastatic breast cancer, significantly prolonged progression-free survival, with no increase in cardiac toxic effects.
Journal ArticleDOI
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain,José Baselga,Sung-Bae Kim,Jungsil Ro,Vladimir Semiglazov,Mario Campone,Eva Ciruelos,Jean-Marc Ferrero,Andreas Schneeweiss,Sarah Heeson,Emma Clark,Graham Ross,Mark C. Benyunes,Javier Cortes,Abstr Act +14 more
TL;DR: In patients with HER2-positive metastatic breast cancer, the addition of pertuzumab to trastuzuab and docetaxel, as compared with the additionof placebo, significantly improved the median overall survival to 56.5 months and extended the results of previous analyses showing the efficacy of this drug combination.
Journal ArticleDOI
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Norikazu Masuda,Soo Jung Lee,Shoichiro Ohtani,Young-Hyuck Im,Eun Sook Lee,Isao Yokota,Katsumasa Kuroi,Seock-Ah Im,Byeong Woo Park,Sung-Bae Kim,Yasuhiro Yanagita,Shinji Ohno,Shintaro Takao,Kenjiro Aogi,Hiroji Iwata,Joon Jeong,Ae-Ree Kim,K. H. Park,Hironobu Sasano,Yasuo Ohashi,Masakazu Toi +20 more
TL;DR: After standard neoadjuvant chemotherapy containing anthracycline, taxane, or both, the addition of adjuvant capecitabine therapy was safe and effective in prolonging disease‐free survival and overall survival among patients with HER2‐negative breast cancer who had residual invasive disease on pathological testing.
Journal ArticleDOI
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
Sandra M. Swain,Sung-Bae Kim,Javier Cortes,Jungsil Ro,Vladimir Semiglazov,Mario Campone,Eva Ciruelos,Jean-Marc Ferrero,Andreas Schneeweiss,Adam Knott,Emma Clark,Graham Ross,Mark C. Benyunes,José Baselga +13 more
TL;DR: A significant improvement in overall survival is shown with pertuzumab, trastuzumAB, and docetaxel in patients with HER2-positive metastatic breast cancer, compared with placebo,trastuzuab, anddocetaxe and this regimen represents a substantial improvement on the standard of care.
Journal ArticleDOI
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
Ian E. Krop,Sung-Bae Kim,Antonio González-Martín,Patricia LoRusso,Jean-Marc Ferrero,Melanie Smitt,Ron Yu,Abraham C. F. Leung,Hans Wildiers +8 more
TL;DR: The final PFS analysis and the first interim overall survival analysis showed a trend favouring trastuzumab emtansine, an antibody-drug conjugate comprising the cytotoxic agent DM1 linked to trastzumab, with treatment of physician's choice in this population of patients.